Table 3: Non-susceptibilities of Pseudomonas aeruginosa of different studies.
Authors |
Period |
Samples |
Population |
Settings |
MDR |
XDR |
PDR |
Colistin NS |
Amikacin NS |
Ceftazidime |
Cefepime NS |
Meropenem |
Piper/Tazo NS |
Ciprofloxacin NS |
Shortridge D, et al. [2] |
1997-2016 |
52022 |
All |
≥ 400 medical centers representing the Asia-Pacific, European, Latin American, and North American regions |
24.9 |
17.6 |
0.1 |
0.6% |
7.0% |
22.5 |
20.7 |
23.9 |
26.9 |
27.1 |
2013-2016 |
16461 |
21.8 |
15.2 |
0.1 |
|
|
19.2 |
|
22.6 |
|
|
|||
BiedenbachDJ, et al. [7] |
2012-2014 |
529 |
hospital-acquired or ventilator-associated pneumonia |
5 medical centers in Vietnam |
- |
- |
- |
- |
18.4 |
57.7 |
39.9 |
43.5 |
43.9 |
45.0 |
Phu VD, et al. [8] |
2012-2013 |
100 |
Hospital-acquired infections |
15 ICU in 14 hospital in Vietnam |
- |
- |
- |
- |
- |
- |
- |
55.7%* |
- |
- |
Pfaller MA, et al. [9] |
2013-2015 |
489 |
All hospitalized patients |
14 medical centers located in 7 countries in the APAC region (minus China, Australia and New Zealand) |
27.4 |
- |
- |
1.6% |
7.8% |
25.8% |
20.9% |
28.3% |
27.9% |
26.0%# |
108 |
|
Korean |
|
|
|
|
|
38.9% |
|
46.3% |
42.6% |
|
||
37 |
|
India |
|
|
|
|
|
32.4% |
|
33.3% |
40.5% |
|
||
138 |
|
Thailand |
|
|
|
|
|
27.5% |
|
33.3% |
29.0% |
|
||
63 |
|
Singapore |
|
|
|
|
|
20.6 |
|
17.5 |
19.0% |
|
||
21 |
|
Taiwan |
|
|
|
|
|
19.0% |
|
19.0 |
25.0% |
|
||
90 |
|
Malaysia |
|
|
|
|
|
14.4 |
|
11.1 |
14.4 |
|
||
32 |
|
Hong Kong |
|
|
|
|
|
12.5 |
|
15.6 |
15.6 |
|
||
Sader HS, et al. [10] |
2012-2015 |
7452 |
All |
79 U.S. medical centers |
15.5 |
9.4 |
- |
0.7 |
3.0 |
15.7 |
14.6 |
18.0 |
19.4 |
22.5 |
Our study |
2019 |
244 |
All |
A hospital in Vietnam |
7.1 |
20.5 |
0.0 |
0.0 |
21.1 |
30.8 |
30.9 |
32.0 |
29.1 |
36.0 |
*Carbapenem resistance; #Levofloxaci